OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Venook Discusses the Role of Chemotherapy in Metastatic CRC

May 11th 2017

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of chemotherapy in metastatic colorectal cancer (CRC).

Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC

May 11th 2017

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of pembrolizumab plus chemotherapy as a frontline treatment for patients with non–small cell lung cancer (NSCLC).

Dr. Beddoe on the Impact of Cervical Cancer Screening

May 11th 2017

Ann Marie Beddoe, MD, assistant professor of Obstetrics, Gynecology and Reproductive Science, Mount Sinai Hospital, discusses the impact of cervical cancer screening for women in the United States.

Dr. Klompenhouwer on the Resection of Larger Hepatocellular Adenomas

May 11th 2017

Anne Julia Klompenhouwer, MD, Department of Surgery at Erasmus Medical Center in Rotterdam, The Netherlands, discusses when it is justified to resect a larger hepatocellular adenoma for patients with hepatocellular carcinoma (HCC).

Dr. Morris on the Next Steps With Bone Biomarkers for Prostate Cancer

May 11th 2017

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the next steps regarding bone biomarkers for patients with prostate cancer.

Dr. Dicker on DNA Sequencing for Prostate Cancer

May 10th 2017

Adam P. Dicker, MD, PhD, professor, chair, Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses DNA sequencing for patients with prostate cancer.

Dr. Siefker-Radtke on FDA Approval of Avelumab in Bladder Cancer

May 10th 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed after platinum-based therapy.

Dr. Slovin on the Challenges of Immunotherapy in Prostate Cancer

May 9th 2017

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the challenges of immunotherapy in prostate cancer.

Dr. Yu on the Significance of the PROTECT Study in Prostate Cancer

May 9th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the significance of the PROTECT study results in prostate cancer.

Dr. Burstein on Adjuvant Endocrine Therapy for ER+ Breast Cancer

May 9th 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses adjuvant endocrine therapy for postmenopausal women with ER-positive breast cancer.

Dr. Meinhardt on the Impact of the RESORCE Study in HCC

May 9th 2017

Gerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma.

Dr. Jain Discusses Treatment of Richter's Transformation in CLL

May 8th 2017

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia who have developed Richter’s transformation.

Dr. Turaga Discusses Current Surgical Setting of Sarcoma

May 8th 2017

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discusses the current surgical setting of sarcoma.

Dr. Carey on De-Escalating Treatments for Triple-Negative Breast Cancer

May 8th 2017

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses de-escalating treatments for patients with triple-negative breast cancer (TNBC).

Dr. Philip on the Importance of Developing New Drugs for Pancreatic Cancer

May 8th 2017

Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the importance of developing new drugs for patients with pancreatic cancer.

The Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

May 8th 2017

Symantha Melemed, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) in patients with soft tissue sarcoma

Dr. Niesvizky on Exciting Changes in the Multiple Myeloma Landscape

May 8th 2017

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.

Dr. Febbo on the Impact of Oncotype DX Genetic Prostate Score

May 6th 2017

Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

Dr. Abou-Alfa on the Role of Immunotherapy in HCC

May 6th 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with hepatocellular carcinoma (HCC).

Dr. Martin on Patient Preferences With MCL Treatment

May 5th 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian, discusses preferences patients have for their treatment of mantle cell lymphoma (MCL).